Eric Pauwels Sells 1,789 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 1,789 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $76.95, for a total value of $137,663.55. Following the completion of the sale, the insider owned 88,841 shares of the company’s stock, valued at approximately $6,836,314.95. This trade represents a 1.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Eric Pauwels also recently made the following trade(s):

• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $104,752.96.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total value of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total transaction of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.06, for a total transaction of $240,342.12.

PTC Therapeutics Trading Up 0.9%

NASDAQ PTCT opened at $77.53 on Friday. The stock has a market cap of $6.22 billion, a P/E ratio of 9.06 and a beta of 0.49. The company’s fifty day simple moving average is $76.61 and its 200-day simple moving average is $62.72. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. During the same quarter in the previous year, the firm posted ($1.39) EPS. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. On average, research analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent quarterly results showed an upside surprise (EPS and revenue beat), supporting valuation and reducing near-term execution risk. MarketBeat PTCT Summary
• Positive Sentiment: At least one independent researcher upgraded PTC from Hold to Buy (Wall Street Zen), and several firms have raised price targets in November — a bullish offset to otherwise muted analyst sentiment. Wall Street Zen Upgrade
• Neutral Sentiment: Analysts as a group still carry a consensus “Hold” rating on PTCT, indicating limited immediate upside from broker consensus alone. Analyst Consensus
• Neutral Sentiment: The company reported a routine inducement grant of 300 RSUs for a new non-executive hire under Nasdaq rules — small dilution and not material to fundamentals. PR Newswire
• Negative Sentiment: A director executed a large sale totaling $916,200, a notable insider disposition that can weigh on sentiment. Director Sale
• Negative Sentiment: Broad insider selling reported in multiple SEC Form 4 filings (CEO, CFO, EVP, VP, CAO and others sold shares in early January). The scale and breadth of executive sales likely represent profit-taking or diversification and can create short-term downward pressure until offset by fresh operational news. Representative SEC filing: SEC Form 4
• Negative Sentiment: EVP Lee Scott Golden and other insiders sold modest-to-large blocks (multiple transactions disclosed), reinforcing the headline of concentrated insider exits. InsiderTrades Alert

Institutional Investors Weigh In On PTC Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PTCT. AlphaQuest LLC lifted its stake in PTC Therapeutics by 337.7% during the second quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 6,102 shares during the last quarter. Vise Technologies Inc. bought a new stake in shares of PTC Therapeutics during the 2nd quarter valued at about $486,000. Prudential Financial Inc. grew its position in shares of PTC Therapeutics by 35.5% during the 2nd quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company’s stock valued at $4,115,000 after buying an additional 22,060 shares during the last quarter. Hussman Strategic Advisors Inc. raised its stake in PTC Therapeutics by 200.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company’s stock worth $3,077,000 after acquiring an additional 42,000 shares during the period. Finally, Y Intercept Hong Kong Ltd lifted its holdings in PTC Therapeutics by 458.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 27,832 shares of the biopharmaceutical company’s stock worth $1,359,000 after acquiring an additional 22,851 shares during the last quarter.

Analysts Set New Price Targets

PTCT has been the subject of a number of analyst reports. Wells Fargo & Company increased their price target on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Barclays upped their target price on PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, November 5th. TD Cowen lifted their price target on shares of PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, November 5th. Finally, Citigroup increased their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $77.27.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.